Abstract 125P
Background
Stage III non-small cell lung cancer (NSCLC) is highly heterogeneous and often warrants multidisciplinary collaboration. Thus, there is a huge unmet need to understand real-world treatment patterns, and relationship to survival outcomes in stage III NSCLC patients.
Methods
MOOREA study is a prospective, non-interventional study to assess the real-world treatment patterns and outcomes of Chinese patients with stage III NSCLC. Treatment naïve stage III NSCLC patients were enrolled and assigned to cohort 1 (unresectable) and cohort 2 (resectable). The primary endpoint is treatment pattern, secondary endpoints are progression-free survival, overall survival, and EGFR/ALK/PD-L1 testing rate. Due to the immaturity of survival endpoints, they will not be reported here.
Results
Between July 2019 and February 2022, 437 eligible patients enrolled from 19 centers in China were included in interim analysis (median age 63 years, 32.3% adenocarcinoma). The testing rates for EGFR, ALK, and PD-L1 were 18.1%, 13.3%, and 10.3%, respectively. In Cohort 1, 41.3% (142/344) patients have received chemoradiotherapy (CRT), including 62.7% (89/142) concurrent CRT (cCRT) and 37.3% (53/142) sequential CRT (sCRT). Of patients after cCRT, 52.8% (47/89) further received consolidation therapy, among which 59.6% (28/47) was immunotherapy. For sCRT patients, 34.0% (18/53) received consolidation therapy, with chemotherapy as the majority (44.4%, 8/18). In Cohort 2, all 93 patients have received surgery and 42.4% (39/92) received neoadjuvant therapy (table).
Table: 125PTreatment patterns in two cohorts
| Cohort 1 (344 pts) | |
|---|---|
| Treatment | |
| CRT | 142/344 (41.3) |
| cCRT | 89/142 (62.7) |
| Consolidation therapy | 47/89 (52.8) |
| sCRT | 53/142 (37.3) |
| Consolidation therapy | 18/53 (34.0) |
| Cohort 2 (93 pts) | |
| Neoadjuvant treatment | |
| Yes | 39/92 (42.4) |
| No | 53/92 (57.6) |
| Missing, n | 1 |
Note: data are presented as n/N (%) except specifically notified.
Conclusions
MOOREA study presents the real-world treatment pattern for stage III NSCLC in China, showing that treatment options for this subset are varied in clinical practice due to disease heterogeneity. Further survival correlations with different treatment patterns are ongoing.
Clinical trial identification
NCT04023812.
Legal entity responsible for the study
The authors.
Funding
AstraZeneca China.
Disclosure
All authors have declared no conflicts of interest.